Vanda sleep drug effective in second late-stage trial
(Reuters) – Vanda Pharmaceuticals Inc said its experimental drug for a rare sleep disorder proved effective in a second late-stage trial, and the company now plans to apply for a U. S. approval for the drug in mid-2013. The study, named Reset, was a 20-patient trial designed to test the maintenance effect of a 20 mg dose of the drug, tasimelteon. Vanda on December 18 said the drug performed better than a placebo in the first of the four planned late-stage trials on the drug. The company’s shares rose as much as 37 percent on that day. . . .
View full post on Health News Headlines – Yahoo! News
Leave a Reply